Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DEPOCYT

« Back to Dashboard
Depocyt is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has twenty-three patent family members in eighteen countries.

The generic ingredient in DEPOCYT is cytarabine. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cytarabine profile page.

Summary for Tradename: DEPOCYT

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Pharmacology for Tradename: DEPOCYT

Clinical Trials for: DEPOCYT

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
Status: Terminated Condition: Neoplastic Meningitis

Depocyt® With Sorafenib in Neoplastic Meningitis
Status: Terminated Condition: Neoplastic Meningitis

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Status: Terminated Condition: Glioblastoma Multiforme; Glioma; Astrocytoma; Brain Tumor

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Status: Suspended Condition: Acute Lymphoblastic Leukemia

DepoCyt for Active Lymphomatous or Leukemic Meningitis
Status: Terminated Condition: Neoplastic Meningitis; Lymphoma, B Cell

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
Status: Completed Condition: Central Nervous System Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
Status: Recruiting Condition: Acute Lymphocytic Leukemia; Adult Lymphoblastic Lymphoma

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
Status: Completed Condition: Meningeal Neoplasms

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Recruiting Condition: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Untreated Adult Acute Myeloid Leukemia

Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer (DEPOSEIN).
Status: Recruiting Condition: Breast Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pacira Pharms Inc
DEPOCYT
cytarabine
INJECTABLE, LIPOSOMAL;INJECTION021041-001Apr 1, 1999RXYes5,723,147<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: DEPOCYT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,807,572 Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride<disabled in preview>
6,071,534 Multivesicular liposomes with controlled release of active agents encapsulated in the presence of a hydrochloride<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DEPOCYT

Country Document Number Publication Date
Finland95439Feb 12, 1996
Portugal86805May 29, 1992
Germany3879987Jul 15, 1993
Japan2843566Jan 06, 1999
Norway880768Aug 24, 1988
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc